Previous 10 | Next 10 |
Clene announced significant updates to their NIH-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8(R) compassionate use in amyotrophic lateral sclerosis (“ALS”) Clene has optimized its manufacturing, operational, and personnel processes...
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has announ...
First patient, first visit is planned for early June 2024 Enrollment has been expanded by 80% to a maximum of 180 participants ‘Real-world’ drug efficacy data will be collected by monitoring potential drug effects on survival and disease progression, as well as safety ...
Clene recently participated in the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference CNM-Au8(R) is oral suspension developed to restore neuronal health and function by increasing energy production and utili...
Clene (NASDAQ: CLNN) has innovated CNM-Au8(R), an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function, which is a significant advancement for the treatment of neurodegenerative disease. “The inspiration for CNM-Au8 comes from the therapeutic potential of ...
Inflammatory bowel disease is an umbrella term for two illnesses: ulcerative colitis and Crohn’s disease. These illnesses are characterized by chronic inflammation of the gastrointestinal tract. On the other hand, Parkinson’s disease is a neurodegenerative illness that affects an...
Clene presented clinical data at the 2024 American Academy of Neurology (“AAN”) Annual Meeting, demonstrating that long-term CNM-Au8® treatment resulted in significant evidence of repair and remyelination across multiple paraclinical endpoints Clene entered into a sub-award g...
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today...
SALT LAKE CITY, May 14, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neurona...
2024-05-08 09:54:58 ET More on Clene Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene Read the full article on Seeking Alpha For further details see: Clene GAAP EPS of -$0.09
News, Short Squeeze, Breakout and More Instantly...
Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a...
Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease . This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubli...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...